Immuno-metabolic depression: from concept to implementation
Year: 2024
Type: review
Abstract: Major depressive disorder is a common, disabling mental disorder characterized by extensive etiological and phenotypic heterogeneity. This heterogeneity makes treatment approaches imprecise and often ineffective. Insight into the underlying biological mechanisms underpinning depression and its subtypes may enable more personalized treatments. In this review, we provide an overview of immuno-metabolic depression and illustrate that significant immuno-metabolic dysregulations are present in about 20-30% of people with depression. Such immuno-metabolic depression is characterized by the clustering of 1) atypical, energy-related depressive symptoms such as hypersomnia, fatigue, hyperphagia, and possibly anhedonia, 2) systemic low-grade inflammation with elevated levels of e.g., C-reactive protein, cytokines and glycoprotein acetyls, and 3) metabolic abnormalities involving e.g., obesity, dyslipidaemia, insulin and leptin resistance. Persons with immuno-metabolic depression are at a higher risk for cardiometabolic diseases and seem to respond less well to standard antidepressant treatment. Interventions targeting inflammation, metabolism or lifestyle may be more effective treatment options for individuals with immuno-metabolic depression, in line with principles of precision psychiatry.
Authors: Brenda W.J.H. Penninx, Femke Lamers, Rick Jansen, Michael Berk, Golam M. Khandaker, Livia De Picker, Yuri Milaneschi
Institutions: Amsterdam Neuroscience, Amsterdam Public Health, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Barwon Health, Deakin University, Avon and Wiltshire Mental Health Partnership NHS Trust, University of Bristol, MRC Integrative Epidemiology Unit, University Hospitals Bristol and Weston NHS Foundation Trust, University of Antwerp
Language: English
Subfield: Biological Psychiatry
Field: Neuroscience
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $4,000
Funders: National Foundation for Medical Research and Innovation, Wellcome Trust, UK Research and Innovation, Amsterdam University Medical Centers, National Institute for Health and Care Research, ZonMw, Ministerie van Onderwijs, Cultuur en Wetenschap, Nederlandse Organisatie voor Wetenschappelijk Onderzoek, Hersenstichting, Amsterdam Neuroscience, Medical Research Council, National Health and Medical Research Council
Awards: G1040531791, G140217044, Development of a bench to bedside platform for novel therapy development for psychiatric disorders, Psychosis Immune Mechanism Stratified Medicine Study (PIMS), Stress-in-Action: Advancing the Science of Stress by Moving the Lab to Daily Life, CHECKPOINT: Finding immune & metabolic pathways to SMI, G4059666690, G4260143917, Inflammation and Immunity in Depression: from novel mechanisms towards therapeutics, G429437450, G4302154454, G462051784, G5189661712, G6342754709, Inflammation and Immunity in Depression: from novel mechanisms towards therapeutics, Physical and mental health multimorbidity across the lifespan (LIfespaN multimorbidity research Collaborative (LINC))., G7383208330, G8476933502, G8496923857, G942680792
OpenAlex ID: W4405540451